CUBIST PHARMACEUTICALS ANNOUNCES POSTING OF BRIEFING DOCUMENTS

Cubist Pharmaceuticals, Inc. today announced that briefing documents prepared by Cubist and the FDA and provided to members of the Anti-Infective Drugs Advisory Committee (AIDAC) are now available to the public. The documents posted on line today by the FDA refer to the sNDA filed by Cubist on September 21, 2005 for an expanded label for CUBICIN(R)(daptomycin for injection) as treatment for Staphylococcus aureus (S. aureus) bacteremia including those with known or suspected endocarditis.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1183601XSL_NEWSML_TO_NEWSML.xml)